ReviewInternational journal of molecular sciences2021
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Leadless ultrasound-based LV endocardial pacing for CRT: systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review.Journal of diabetes research · 2024Pooled it
- Correlation between osteoprotegerin and coronary artery calcification in diabetic subjects: a systematic review of observational studies.BMC cardiovascular disorders · 2023Pooled it
- The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial.European journal of clinical pharmacology · 2026Trial
- Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.Open heart · 2022Trial
- SGLT2 inhibition improves sarcomere contractile dysfunction in human models of dilated cardiomyopathy.Journal of translational medicine · 2026Article
- Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection.Indian journal of pharmacology · 2026Review
- Review
- Astragaloside IV Ameliorates Diabetic Cardiomyopathy by Suppressing the GNG2/MRAS-ERK Signaling Pathway.International journal of general medicine · 2026Article
- Therapeutic Advances in Diabetic Kidney Disease: 30 Years of Evidence and the Rise of the "Fantastic Four" in Nephrology.Cardiorenal medicine · 2026Review
- Fried Frailty Phenotype and 6-Month Risk of First All-Cause Rehospitalisation Among Older Outpatients with Heart Failure and LVEF >40%: A Multicentre Prospective Cohort Study.International journal of general medicine · 2026Article
- Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health.Current pharmaceutical design · 2026Review
- Case Report: Bexagliflozin as an adjunct decongestive strategy in a cat with congestive heart failure and advanced chronic kidney disease.Frontiers in veterinary science · 2026Article
- Remodeling of Cardiac Macrophage Subsets Serves as a Critical Driver of Early Diabetic Myocardial Injury.Journal of inflammation research · 2026Article
- Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management.International journal of molecular sciences · 2025Review
- SGLT-2 Inhibitors in the Prevention and Progression of Neurodegenerative Diseases: A Narrative Review.Neurology and therapy · 2025Review
- Efficacy and Safety of Sildenafil in Combination with Dapagliflozin Versus Dapagliflozin Monotherapy in the Management of Heart Failure with Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Hypertension and Diabetes as Determinants of Patient-Reported Quality of Life in Permanent Atrial Fibrillation.Diagnostics (Basel, Switzerland) · 2025Article
- Initial Dip in Estimated Glomerular Filtration Rate After Dapagliflozin Affects Renal Function in Chronic Phase in Chronic Heart Failure.Journal of clinical medicine · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status induced by insulin resistance are crucial in cardiac function impairment, SGLT2i cardioprotective mechanisms against HF are several. In particular, these beneficial effects seem attributable to the significant reduction of intracellular sodium levels, well-known to exert a cardioprotective role in the prevention of oxidative stress and consequent cardiomyocyte death. From a molecular perspective, patients' exposure to gliflozins' treatment mimics nutrient and oxygen deprivation, with consequent autophagy stimulation. This allows to maintain the cellular homeostasis through different degradative pathways. Thus, since their introduction in the clinical practice, the hypotheses on SGLT2i mechanisms of action have changed: from simple glycosuric drugs, with consequent glucose lowering, erythropoiesis enhancing and ketogenesis stimulating, to intracellular sodium-lowering molecules. This provides their consequent cardioprotective effect, which justifies its significant reduction in CV events, especially in populations at higher risk. Finally, the updated clinical evidence of SGLT2i benefits on HF was summarized. Thus, this review aimed to analyze the cardioprotective mechanisms of sodium glucose transporter 2 inhibitors (SGLT2i) in patients with HF, as well as their clinical impact on cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.